Hims and his close dermatology business

• Hims and his close the dermatology company she acquired in 2021, learned Bi.
• The company said it closed the apostrophe of the skin care site to centralize its teledermatology offers.
• The stock of Hims and His was madly this year while his weight loss business faces new pressures.

Hims and his close his dermatology business, learned Business Insider.

Friday, the Télésanté company interrupted the apostrophe, the startup for direct skin care for consumers that Hims and its own bought in 2021 for $ 190 million.

According to a message on the apostrophe website, all subscriptions will be canceled on March 7 and customers will lose access to their supplier teams and their patient accounts after 30 days. The message suggested visiting it and its own to pursue skin care treatment.

“After a meticulous examination, we delete the apostrophe to simplify our dermatology products and operations in a single transparent experience for our customers and our continuous objective to give customers access to the most effective care,” said Hims and his in a statement to Bi.

Hims and his have already offered dermatology services before buying the apostrophe and continued to provide them after the acquisition. The company, which offers a variety of services via its online platform, including hair loss treatments, erectile dysfunction and mental health, said that the apostrophe of closing will help it centralize its skin care offers for customers.

According to the company, the closure is not linked to future changes in its weight loss activity or pressure on its stock, which has dropped At 27% last month after the Food and Drug Administration declared the end of the semaglutide shortage, the active ingredient in successful successful weight loss drugs and Wegovy.

HIMS and his own took great on the prescription of the composition versions of these weight loss drugs, in particular by buying his own pharmacy to worsen in September. The FDA allowed pharmacies to make versions made up of semaglutide since 2022 to expand patient access to medicines.

But with the shortage now finished, the company will no longer be able to make versions of copying the blows.

The company’s financial director, Yemi Okupe, confirmed after the benefits of the fourth quarter of Hims and HIS that the company plans to remove all the doses of semaglutide available in the trade in its platform.

Hims and his heard a strong year in 2024 on the growth of its weight loss activity. Its income jumped 69% to 1.48 billion dollars, its GLP-1 offering collecting $ 225 million.

The company said it is still expecting its generous weight loss activity of 725 million dollars in 2025, excluding semaglutide doses available in the trade. Him and his own Will continue to offer weight loss pills and personalized weight loss support, including nutrition plans and coaching.

The stock has been up 40% since the start of the year, culminating in mid-February after Hims and his own published a controversial advertisement on its weight loss platform during the Super Bowl and announced next week that it had bought the Trybe Labs home laboratory test.